Patents Assigned to National Centre for Cell Sciences
-
Patent number: 11478532Abstract: The present invention discloses a novel therapeutic intervention for osteoporosis. The present invention discloses that Interleukin-3 (IL-3) can be utilized as a therapeutic intervention against osteoporosis and for regulating bone homeostasis. The present invention also provides a method for determining the pre-disposition of a subject for osteoporosis by measuring the RANKL/OPG level.Type: GrantFiled: December 3, 2018Date of Patent: October 25, 2022Assignee: NATIONAL CENTRE FOR CELL SCIENCEInventors: Kanupriya Singh, Mohan Ramchandra Wani
-
Publication number: 20220195012Abstract: The complement system is part of the innate immune system and is highly regulated by regulatory proteins belonging to the Regulators of Complement Activation (RCA) family. It is known that lack of regulation causes damage to host cells and deficiencies in the regulation is also linked to diseases such as age-related macular degeneration, atypical hemolytic uremic syndrome, and dense deposit disease. The regulatory proteins primarily include decay-accelerating factor (DAF; CD55), membrane cofactor protein (MCP; CD46), complement receptor 1 (CR1; CD35), factor H (FH) and C4b-binding protein (C4BP). Structurally, these proteins are composed of repeating complement control protein (CCP) domains where 2-4 successive domains contribute to the regulatory functions termed as decay-accelerating activity (DAA) and cofactor activity (CFA). However, no four-domain chimeric protein currently exists having both strong DAA (CP-DAA and AP-DAA) and strong CFA (C3b-CFA and C4b-CFA). Therefore, chimeric protein DCP (i.e.Type: ApplicationFiled: April 9, 2020Publication date: June 23, 2022Applicant: NATIONAL CENTRE FOR CELL SCIENCEInventors: Arvind SAHU, Hemendra Singh PANWAR, Hina OJHA, Payel GHOSH, Sagar H. BARAGE
-
Publication number: 20210338611Abstract: The present invention pertains to a synergistic combination comprising histone deacetylase inhibitors (HDACi) in combination with estrogen receptor (ER) antagonist for treating gliomas. The present invention also discloses composition containing the combination, and a method of use of the combination and the composition of the present invention and method of treatment using the combination.Type: ApplicationFiled: September 5, 2019Publication date: November 4, 2021Applicant: NATIONAL CENTRE FOR CELL SCIENCEInventor: Padma SHASTRY
-
Publication number: 20210196718Abstract: The present invention relates to compounds and pharmaceutical composition having antiviral effects. Over 1200 molecules were screened and 55 molecules having statistically significant anti-HIV activity were identified and selected. The compound Methotrexate (MTX-HYD) and its analogues, the combinations thereof and their combination with other anti-retrovirals were selected for repurposing the compounds as anti-HIV drugs. The present invention may further relate to pharmaceutical composition comprising compounds in combination with active drugs having anti-HIV activity.Type: ApplicationFiled: May 10, 2019Publication date: July 1, 2021Applicant: NATIONAL CENTRE FOR CELL SCIENCEInventors: Debashis MITRA, Jay TRIVEDI
-
Patent number: 10429393Abstract: The present invention provides a method for concurrent resolution of the cancer stem cell (CSC) derived hierarchy, genetic instability, differentially cycling cells and host cells recruited for performing tumor growth supporting functions; and (ii) quantification, monitoring and analysis of these populations. The first level of analysis can be carried out using either CSC- and progenitor-specific markers or a marker-free approach based on label-chase to resolve the tumor regenerative hierarchy. The next level involves combinatorial quantification of differential DNA-RNA contents to identify recruited host and tumor cell variants resulted from genetic instability and differential cycling within the tumor.Type: GrantFiled: January 17, 2015Date of Patent: October 1, 2019Assignee: NATIONAL CENTRE FOR CELL SCIENCEInventors: Sharmila A. Bapat, Rutika R. Naik
-
Publication number: 20190175700Abstract: The present invention discloses a novel therapeutic intervention for osteoporosis. The present invention discloses that Interleukin-3 (IL-3) can be utilized as a therapeutic intervention against osteoporosis and for regulating bone homeostasis. The present invention also provides a method for determining the pre-disposition of a subject for osteoporosis by measuring the RANKL/OPG level.Type: ApplicationFiled: December 3, 2018Publication date: June 13, 2019Applicant: NATIONAL CENTRE FOR CELL SCIENCEInventors: Kanupriya Singh, Mohan Ramchandra Wani
-
Publication number: 20170067901Abstract: The present invention provides a method for concurrent resolution of the cancer stem cell (CSC) derived hierarchy, genetic instability, differentially cycling cells and host cells recruited for performing tumor growth supporting functions; and (ii) quantification, monitoring and analysis of these populations. The first level of analysis can be carried out using either CSC- and progenitor-specific markers or a marker-free approach based on label-chase to resolve the tumor regenerative hierarchy. The next level involves combinatorial quantification of differential DNA-RNA contents to identify recruited host and tumor cell variants resulted from genetic instability and differential cycling within the tumor.Type: ApplicationFiled: January 17, 2015Publication date: March 9, 2017Applicant: National Centre for Cell ScienceInventors: Sharmila A. BAPAT, Rutika R. NAIK
-
Patent number: 8865237Abstract: A method of preparing dialysed aqueous extract of fenugreek seeds comprising washing the fenugreek seeds is distilled water, sterilizing the said seeds, subjecting the sterilized seeds to the step of grinding to form powder, suspending the said powder in phosphate buffered saline (PBS), subjecting the said suspension to the step of filtration to obtain the filtrate, treating the filtrate with activated charcoal to obtain clear supernatant, subjecting the supernatant to the step of lyophilization and the powder thus obtained was dissolved in phosphate buffered saline (PBS), dialyzing the aqueous extract of fenugreek seeds to obtain dialysed fenugreek seed extract (FSE) which was aliquoted and stored.Type: GrantFiled: June 27, 2006Date of Patent: October 21, 2014Assignees: Department of Biotechnology, National Centre For Cell ScienceInventors: Manoj Kumar Bhat, Maleppillil Vavachen Vijayakumar
-
Patent number: 8519163Abstract: A novel chemical moiety triterpenoid AECHL-1 isolated from root bark of Ailanthus excelsa having the structure:Type: GrantFiled: December 2, 2008Date of Patent: August 27, 2013Assignees: National Centre for Cell Science, Department of BiotechnologyInventors: Sandhya Sitasawad, Manish Lavhale, Santosh Kumar, Shrihari Mishra
-
Patent number: 8420100Abstract: Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus.Type: GrantFiled: September 10, 2007Date of Patent: April 16, 2013Assignees: Department of Biotechnology, National Centre for Cell ScienceInventors: Samit Chattopadhyay, Archana Jalota-Badhwar
-
Publication number: 20110046342Abstract: Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus.Type: ApplicationFiled: September 10, 2007Publication date: February 24, 2011Applicants: Department of Biotechnology, National Centre for Cell ScienceInventors: Samit Chattopadhyay, Archana Jalota-Badhwar
-
Publication number: 20100311987Abstract: A novel chemical moiety triterpenoid AECHL-1 isolated from root bark of Ailanthus excelsa having anti-cancer properties exhibiting remarkable activity in treatment of various forms of tumors with specificity wherein it blocks the growth of four tumor cell lines with distinct origins and of different p53 status (B16F10 mouse melanoma, PC3 human prostate cancer, MCF-7 and MDA-MB-231 human breast cancer), having following characteristic IR, NMR and mass spectra IR (KBr): 3425, 3419 (hydroxyl group), 2972, 2966, 2923, 2873 (alkyl C—H stretch), 1733 (? lactone), 1718 (Bi acetyl), 1680 (C?O conjugation with alkene), 1652 (—C?C stretching), 1600 (aromatic), 1492, 1454, 1394 (methyl stretching), 1222 (? lactone), 1184, 1110, 1051, 1031 (acetals), 1018 nm (alkanes). 1H-NMR (DMSO, 400 Hz) ?: 0.95 (3H, t, 4?-CH3), ?:1.15 (3H, d, H-24), ?:1.235 (3H, d, 5?-CH3), ?: 1.5 (2H, ddd, 5?-CH2), ?: 1.73 (3H, ddd, H-21), ?: 1.83 (1H, s, H-9), ?: 1.87 (1H, s, H-14), ?: 1.9 (2H, s, H-18), ?: 2.16 (3H, s, H-18), ?: 2.Type: ApplicationFiled: December 2, 2008Publication date: December 9, 2010Applicants: National Centre For Cell Science, Department of BiotechnologyInventors: Sandhya Sitasawad, Manish Lavhale, Santosh Kumar, Shrihari Mishra
-
Publication number: 20090305325Abstract: Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.Type: ApplicationFiled: June 27, 2006Publication date: December 10, 2009Applicants: DEPARTMENT OF BIOTECHNOLOGY, NATIONAL CENTRE FOR CELL SCIENCE, INDIAN INSTITUTE OF SCIENCESInventors: Vaijayanti P. Kale, Lalita S. Limaye, Ashwini Hinge, Avadhesha Surolia
-
Patent number: 7604980Abstract: The present invention relates to proteomics, especially downstream processing of proteins. The present invention also relates to novel expression cassettes having unique cleavage sites for efficient removal of purification tags. The invention further provides expression systems and a methods for purifying and isolating proteins.Type: GrantFiled: February 2, 2006Date of Patent: October 20, 2009Assignee: National Centre for Cell ScienceInventors: Sanjeev Galande, Prabhat K. Purbey, Peter C. Jayakumar, Milind S. Patole
-
Publication number: 20090226554Abstract: A method of preparing dialysed aqueous extract of fenugreek seeds comprising washing the fenugreek seeds is distilled water, sterilizing the said seeds, subjecting the sterilized seeds to the step of grinding to form powder, suspending the said powder in phosphate buffered saline (PBS), subjecting the said suspension to the step of filtration to obtain the filtrate, treating the filtrate with activated charcoal to obtain clear supernatant, subjecting the supernatant to the step of lyophilization and the powder thus obtained was dissolved in phosphate buffered saline (PBS), dialyzing the aqueous extract of fenugreek seeds to obtain dialysed fenugreek seed extract (FSE) which was aliquoted and stored.Type: ApplicationFiled: June 27, 2006Publication date: September 10, 2009Applicant: National Centre for Cell SciencesInventors: Manoj Kumar Bhat, Maleppillil Vavachen Vijayakumar
-
Publication number: 20070037251Abstract: The present invention relates to proteomics, especially downstream processing of proteins. The present invention also relates to novel expression cassettes having unique cleavage sites for efficient removal of purification tags. The invention further provides expression systems and a methods for purifying and isolating proteins.Type: ApplicationFiled: February 2, 2006Publication date: February 15, 2007Applicant: National Centre for Cell SciencesInventors: Sanjeev Galande, Prabhat Purbey, Peter Jayakumar, Milind Patole
-
Publication number: 20050037434Abstract: The present invention relates to a monoclonal antibody directed against the 150 kDa protein M150 on activated macrophages.Type: ApplicationFiled: August 13, 2004Publication date: February 17, 2005Applicant: National Centre for Cell ScienceInventors: Durbaka Prasad, Pradeep Parab, Gyan Mishra